Skip to content

Optimization of a New Adaptive Intervention to Increase COVID-19 Testing

Optimization of a New Adaptive Intervention to Increase COVID-19 Testing Among People at High Risk in an Urban Community

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04757298
Enrollment
668
Registered
2021-02-17
Start date
2021-02-12
Completion date
2022-10-25
Last updated
2024-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Testing

Brief summary

This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. This study uses an integrated research collaborative framework that facilitates dialogue among researchers, community members, and service providers as a tool for optimizing the adaptive intervention and will take place at the North Jersey Community Research Initiative (NJCRI)

Detailed description

This study will use the Multiphase Optimization Strategy (MOST) to optimize an adaptive intervention that successfully navigates COVID-19 medically or socially vulnerable people through a continuum of prevention, care and treatment (CoPCT) modeled on the HIV CoPCT. The COVID-19 CoPCT starts with testing and continues with successful adherence to prevention or treatment guidelines to help prevent and/or treat COVID-19. The study will assess the effectiveness of Navigation Services compared to referrals in increasing COVID-19 testing and Brief Counseling in increasing adherence to the State of NJ recommendations for COVID-19 prevention and treatment. The study will also examine the effect of Critical Dialogue on testing behavior among people who decline to be tested for COVID-19. The investigators will develop decision rules about what evidence-based-interventions work best for what types of people (e.g., those who test right away, versus decliners) and in what period of the COVID-19 continuum. Finally, the study will shed light on factors associated with testing and adherence to NJ recommendations. Investigators will follow Community Based Participatory Research principles in implementing a sequential, multiple assignment randomized trial (SMART) design. Adjusting for possible 15% loss to follow-up, a total sample of 670 people who are medically and socially vulnerable to infection and poor outcomes with COVID-19 will be enrolled as the intent-to treat-sample. The investigators are confident that they can recruit this sample in Essex County, NJ based on their previous experience and because the parent study research team has established relationships with other service agencies in the community from which, in addition to NJCRI, research participants will be drawn. The primary outcome is completion of the COVID-19 test within one week of the first intervention session The study will include 3 stages in which participants will be randomized to one of two possible interventions as follows: 1. Eligible and consenting participants will be randomized to receive the first-stage intervention: Navigation Services (NS) or standard services (referral to testing and NJ digital information brochure after testing). The primary outcome is completion of the COVID-19 test within one week of the intervention session. 2. Those who get tested will be randomized to receive the second-stage intervention: continue with NS or standard treatment or switch to Brief Counseling (BC). The outcome will be adherence to NJ recommendations. For those testing positive, adherence means engaging in a 14-day quarantine, receiving medical care as needed and contact tracing. For those testing negative, adherence means social distancing and wearing masks. 3. Those who do not get tested will be randomized into their second-stage intervention to continue with NS or digital brochure or switch to Critical Dialogue (CD). The outcome will be completing COVID-19 testing within 1 week of the second stage intervention session. Those who complete the testing will then be randomized to either continue with NS or digital brochure or switch to BC. Those who do not get tested will be randomized to continued NS or digital brochure or switch to CD. The outcome will be adherence to NJ recommendations, as defined above. All variables will be measured using standardized measures selected from the National Institutes of Health (NIH) PhenX Toolkit. For the primary aim of comparing effects of Navigation Services versus referral on testing behavior and NJ recommendations adherence, using standard sample size formula for difference of two proportions, a total sample size of 582 subjects is needed to have 80% power at α=0.05 to detect a 10% difference in proportions, assuming 70% in the referral group will complete testing and adhere to specific NJ recommendations. The 582 sample size has 85% to detect a difference of 15% in adherence rates to NJ recommendations between two interventions.

Interventions

Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services

Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.

Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.

Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.

Sponsors

North Jersey Community Research Initiative
CollaboratorOTHER
National Institute on Minority Health and Health Disparities (NIMHD)
CollaboratorNIH
University of Michigan
CollaboratorOTHER
University of Illinois at Urbana-Champaign
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

SMART Design

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* over 18 years of age * having high risk to contract COVID or develop related complications * able to speak English * able and willing to provide informed consent.

Exclusion criteria

* under 18 years of age * not at high risk to contract COVID or develop related complications * unable to speak English * unable and unwilling to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Stage 1: Completion of COVID-19 Test After First RandomizationStage 1: Within one week of completing baseline.For the first stage intervention, the primary outcome is coming to the agency and completing the COVID-19 antigen test one week after completing the baseline.
Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineStage 2: 6 months post baseline (4th follow up visit)For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days.

Countries

United States

Participant flow

Recruitment details

Participants were recruited into the study at the North Jersey Community Research Initiative (NJCRI), one of New Jersey's largest and most comprehensive HIV/AIDS community-based organization.

Participants by arm

ArmCount
Navigation (1)+ Navigation (2)
Participants in this group were randomized in Stage 1 to receive Navigation Services and randomized to receive Navigation Services in Stage 2. Navigation Services: Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
160
Navigation (1) + Brief Counseling (2)
Participants in this Group were randomized to receive Navigation services in Stage 1 and randomized to receive Brief Counseling in Stage 2. Brief Counseling: Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
36
Navigation (1) + Critical Dialogue (2)
Participants in this group were randomized to receive Navigation Services in Stage 1 and randomized to receive Critical Dialogue in Stage 2. Critical Dialogue: Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities
126
Brochure (1) + Brochure (2)
Participants in this group were randomized in stage 1 to receive a digital brochure and randomized to receive a digital brochure in Stage 2. Referral and Digital Brochure: Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
165
Brochure (1)+ Brief Counseling (2)
Participants in this group were randomized in Stage 1 to receive a Brochure and were randomized to receive Brief Counseling in Stage 2. Brief Counseling: Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
32
Brochure (1) + Critical Dialogue (2)
Participants in this group were randomized to receive Navigation Services in Stage 1 and were randomized to receive Critical Dialogue in Stage 2. Critical Dialogue: Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
137
Total656

Baseline characteristics

CharacteristicNavigation (1) + Brief Counseling (2)Navigation (1) + Critical Dialogue (2)Brochure (1) + Brochure (2)Brochure (1)+ Brief Counseling (2)Brochure (1) + Critical Dialogue (2)Navigation (1)+ Navigation (2)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2 Participants4 Participants6 Participants2 Participants5 Participants7 Participants26 Participants
Age, Categorical
Between 18 and 65 years
34 Participants122 Participants159 Participants30 Participants132 Participants153 Participants630 Participants
COVID tested within previous 30 days12 Participants26 Participants40 Participants8 Participants39 Participants40 Participants165 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants17 Participants25 Participants4 Participants24 Participants22 Participants96 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
30 Participants105 Participants133 Participants23 Participants105 Participants133 Participants529 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants4 Participants7 Participants5 Participants8 Participants5 Participants31 Participants
Race/Ethnicity, Customized
American Indian or Alaskan Native
0 Participants7 Participants7 Participants1 Participants8 Participants10 Participants33 Participants
Race/Ethnicity, Customized
Asian
0 Participants6 Participants3 Participants0 Participants0 Participants0 Participants9 Participants
Race/Ethnicity, Customized
Black or African American
31 Participants99 Participants127 Participants26 Participants99 Participants127 Participants509 Participants
Race/Ethnicity, Customized
Missing/Not Reported
0 Participants0 Participants1 Participants2 Participants2 Participants1 Participants6 Participants
Race/Ethnicity, Customized
Native Hawaiian or Pacific Islander
0 Participants2 Participants2 Participants0 Participants4 Participants1 Participants9 Participants
Race/Ethnicity, Customized
Other or Unknown
2 Participants7 Participants16 Participants2 Participants14 Participants14 Participants55 Participants
Race/Ethnicity, Customized
White
3 Participants12 Participants16 Participants2 Participants12 Participants19 Participants64 Participants
Region of Enrollment
United States
36 participants126 participants165 participants32 participants137 participants160 participants656 participants
Sex/Gender, Customized
Female
10 Participants53 Participants67 Participants12 Participants57 Participants72 Participants271 Participants
Sex/Gender, Customized
Gender Missing/Unknown
0 Participants0 Participants1 Participants1 Participants0 Participants0 Participants2 Participants
Sex/Gender, Customized
Male
25 Participants68 Participants90 Participants19 Participants76 Participants86 Participants364 Participants
Sex/Gender, Customized
none of these describe me (includes those identifying as non-binary, transgender, and bi-gender)
1 Participants5 Participants7 Participants0 Participants4 Participants2 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
deaths
Total, all-cause mortality
0 / 3280 / 1600 / 360 / 1260 / 3400 / 1650 / 320 / 137
other
Total, other adverse events
0 / 3280 / 1600 / 360 / 1260 / 3400 / 1650 / 320 / 137
serious
Total, serious adverse events
0 / 3280 / 1600 / 360 / 1260 / 3400 / 1650 / 320 / 137

Outcome results

Primary

Stage 1: Completion of COVID-19 Test After First Randomization

For the first stage intervention, the primary outcome is coming to the agency and completing the COVID-19 antigen test one week after completing the baseline.

Time frame: Stage 1: Within one week of completing baseline.

Population: Population for Stage 1

ArmMeasureGroupValue (NUMBER)
Navigation (1)Stage 1: Completion of COVID-19 Test After First RandomizationStage 1 COVID tested78 participants
Navigation (1)Stage 1: Completion of COVID-19 Test After First RandomizationMissing/Unknown0 participants
Brochure OnlyStage 1: Completion of COVID-19 Test After First RandomizationStage 1 COVID tested71 participants
Brochure OnlyStage 1: Completion of COVID-19 Test After First RandomizationMissing/Unknown0 participants
Primary

Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline

For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days.

Time frame: Stage 2: 6 months post baseline (4th follow up visit)

Population: Population includes baseline at Stage 2.

ArmMeasureGroupValue (NUMBER)
Navigation (1)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineMissing0 participants
Navigation (1)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineReported COVID tested in prior 30 days40 participants
Brochure OnlyStage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineMissing18 participants
Brochure OnlyStage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineReported COVID tested in prior 30 days12 participants
Navigation (1) + Critical Dialogue (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineReported COVID tested in prior 30 days26 participants
Navigation (1) + Critical Dialogue (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineMissing57 participants
Brochure (1) + Brochure (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineReported COVID tested in prior 30 days40 participants
Brochure (1) + Brochure (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineMissing78 participants
Brochure (1)+ Brief Counseling (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineReported COVID tested in prior 30 days8 participants
Brochure (1)+ Brief Counseling (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineMissing16 participants
Brochure (1) + Critical Dialogue (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineMissing53 participants
Brochure (1) + Critical Dialogue (2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineReported COVID tested in prior 30 days39 participants

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026